23rd Aug 2006 07:01
Vernalis PLC23 August 2006 23 August 2006 Vernalis: Notice of Interim Financial Results Vernalis plc (LSE: VER, Nasdaq: VNLS) today announces that it will be releasingits interim results for the six months ended 30 June 2006 on Tuesday, 12September 2006. An analyst briefing will be held at 9.00 a.m. on 12 September at The RoyalCollege of Surgeons, 35-43 Lincoln's Inn Fields, London. WC2A 3PE. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief Executive OfficerTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communication Brunswick Group +44 (0) 20 7404 5959Jon ColesJustine McIlroy About VernalisVernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec, Serono and Chiesi. Vernalis has established a US commercialoperation to promote Apokyn(R) and co-promote Frova(R) alongside its NorthAmerican licensing partner, Endo Pharmaceuticals, propelling the company towardsits goal of becoming a sustainable, self-funding, R&D-driven, specialitybio-pharmaceutical company. For further information about Vernalis, please visitwww.vernalis.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC